-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gemcitabine Hydrochloride in Transitional Cell Cancer (Urothelial Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gemcitabine Hydrochloride in Transitional Cell Cancer (Urothelial Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gemcitabine Hydrochloride in Transitional Cell Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darleukin in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darleukin in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darleukin in Melanoma Drug Details: Darleukin (L19-IL2) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-718 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-718 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-718 in Acute Lymphocytic Leukemia (ALL,...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Antibody drug conjugates(ADC) cancer therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dodekin in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dodekin in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dodekin in Melanoma Drug Details: Dodekin is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dodekin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dodekin in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dodekin in Non-Small Cell Lung Cancer Drug Details: Dodekin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fibromun in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fibromun in Melanoma Drug Details: Fibromun (L19-TNF alpha monoclonal antibody-cytokine fusion protein)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fibromun in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fibromun in Solid Tumor Drug Details: Fibromun (L19-TNF alpha monoclonal antibody-cytokine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fibromun in Malignant Fibrous Histiocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Malignant Fibrous Histiocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fibromun in Malignant Fibrous Histiocytoma Drug Details: Fibromun (L19-TNF alpha...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fibromun in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fibromun in Soft Tissue Sarcoma Drug Details: Fibromun (L19-TNF alpha...